Yentreve

Selected form

Duloxetine

Method of action: Antidepressant, Psychoanaleptics

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Yentreve

What is Yentreve?

Yentreve is a brand-name medication containing the active substance duloxetine. It belongs to a group of medicines known as selective serotonin and norepinephrine reuptake inhibitors (SNRIs). These substances work by increasing the levels of two chemical messengers, serotonin and norepinephrine, within the nervous system.

Mechanism of Action

In the context of its specific therapeutic use, duloxetine works by increasing the activity of the neurotransmitters in the nerves that control the urethral sphincter. The mechanism is designed to strengthen the closure of the urethra during moments of physical pressure or sudden movements.

Primary Use

Yentreve is specifically indicated for the management of moderate to severe Stress Urinary Incontinence (SUI) in women. SUI is a condition characterized by the accidental leakage of urine during physical exertion or activities that increase abdominal pressure, such as:

Sneezing or coughing
Laughing
Lifting heavy objects
Exercise or jumping

By enhancing the tone of the muscles surrounding the urethra, the medication helps to prevent involuntary leakage during these activities. It is often used as part of a broader treatment plan that may include pelvic floor muscle training.

What side effects are possible with Yentreve?

Possible side effects and safety information

The safety profile of Yentreve (duloxetine) is structured by governmental regulatory authorities to categorize and communicate potential adverse reactions and safety restrictions. Side effects are classified based on their frequency of occurrence, as documented in official prescribing information.

Adverse Reaction Classifications

Frequency Category	Examples of Officially Documented Adverse Reactions
Very Common (may affect more than 1 in 10 people)	Nausea, Dry mouth, Constipation, Fatigue
Common (may affect up to 1 in 10 people)	Dizziness, Headache, Somnolence (drowsiness), Decreased appetite, Hyperhidrosis (increased sweating)

These effects are grouped into System-Organ Classes, primarily involving Gastrointestinal disorders and Nervous system disorders.

Serious Safety Considerations and Constraints

Official regulatory documents note a number of serious, though less frequent, safety concerns. These include the potential for Hepatic failure and the recognized risk of Suicidal thoughts and behavior, particularly upon treatment initiation or following dose changes. The label also documents the risk of Serotonin Syndrome and severe skin reactions, such as Stevens-Johnson Syndrome.

Safety constraints and limitations are explicitly defined. Yentreve is contraindicated (should not be used) in individuals with uncontrolled or severe hypertension, severe hepatic impairment, or severe renal impairment (GFR below 30 mL/min). The regulatory labeling includes specific safety notes for certain patient populations, such as older adults and those with pre-existing liver or kidney disease.

Overdose and Emergency Response

The official regulatory documentation identifies that overdose with the active ingredient duloxetine may present with several clinical and physiological manifestations. These documented signs and symptoms include somnolence (drowsiness), vomiting, syncope (fainting), and disturbances in cardiovascular function such as tachycardia (rapid heart rate) and fluctuations in blood pressure (hypotension or hypertension).

More severe or life-threatening outcomes have also been reported and require urgent attention. These complications include coma, seizures, respiratory depression, and the potentially severe condition known as Serotonin syndrome. Fatal outcomes have been reported following both mixed-drug overdoses and overdoses with duloxetine alone, with co-ingestion of multiple drugs being noted in the regulatory findings as a primary factor associated with the most severe results.

Given the potential for these serious manifestations, immediate medical attention must be sought for all suspected or confirmed cases of overdose. The regulatory guidance explicitly states that no specific antidote is known for duloxetine. Therefore, the required management protocol is symptomatic and supportive, mandating continuous monitoring of cardiac and vital signs. Procedures such as the administration of activated charcoal and gastric lavage are officially described measures that may be considered by medical professionals to limit systemic absorption when clinically appropriate.

Therapeutic Uses of Yentreve

What Yentreve Treats: Main Uses and Benefits

Yentreve is used to help manage the symptoms of moderate to severe Stress Urinary Incontinence (SUI) in adult women. This treatment is applied when additional symptomatic support is needed for conditions where symptoms may intensify, and it is considered relevant when assistance is required to address increased physical discomfort.

Therapeutic Focus and Symptom Relief

Yentreve is used for managing the clusters of symptoms related to involuntary urine leakage that occur during physical stress. This involves addressing the accidental loss of urine during common actions like coughing, sneezing, laughing, or during physical exertion. It is applied in situations where these symptoms create noticeable functional strain and interfere with daily activities. The primary therapeutic benefit contributes to easing the overall symptom burden by helping to reduce the frequency of urine loss episodes.

This supportive relief is utilized for patients whose SUI symptoms are classified as moderate to severe. The treatment is often used as a pharmacological support alongside behavioral strategies such as Pelvic Floor Muscle Training (PFMT). By assisting with the management of these symptomatic patterns, the medication contributes to improved comfort during symptomatic periods, supporting general well-being and assisting with functional stability during routine activities.

Quick Fact: Relief for Stress Urinary Incontinence

Quick Fact: Relief for Stress Urinary Incontinence
Yentreve is used for managing moderate to severe SUI, offering supportive relief for involuntary leakage tied to physical stressors and contributing to improved day-to-day comfort.

Eligibility and Restrictions for Use

Official Population Eligibility for Yentreve

The eligibility for using Yentreve (duloxetine) is strictly defined by regulatory authorities and is primarily indicated for adult women with moderate to severe Stress Urinary Incontinence (SUI). Official labeling specifies several populations for whom use is strictly contraindicated or not recommended.

Contraindicated Populations (Must Not Use)	Age/Condition Restrictions
Patients with severe hepatic impairment or severe renal impairment (CrCl < 30 ml/min).	Children and adolescents under 18 (not recommended; safety not established).
Patients with uncontrolled hypertension.	Pregnant or breastfeeding women (not recommended).
Patients taking a non-selective, irreversible Monoamine Oxidase Inhibitor (MAOI).	Older adults (> 65 years) (use with caution).
Individuals with hypersensitivity to duloxetine.	Patients with history of seizures or mania (use with caution).

The medicine is not recommended for use in women who are pregnant or breastfeeding, as documented in official labeling. Use with caution is also required for patients with pre-existing conditions like increased intraocular pressure, and those with certain genetic metabolic disorders, such as sucrose-isomaltase insufficiency, are also prohibited from using this medicine. These restrictions ensure alignment with the official, labeled conditions of use.

What should I know about interactions with other medicines?

Yentreve (duloxetine) can interact with a number of other medicines and products, which may increase the risk of certain side effects or raise the concentration of duloxetine in the body.

Contraindicated Combinations

Yentreve is contraindicated (should not be used) in combination with two main categories of medicines:

Nonselective, irreversible Monoamine Oxidase Inhibitors (MAOIs), such as phenelzine and tranylcypromine, due to a severe risk of Serotonin Syndrome. A 14-day wash-out period is required after stopping an MAOI before starting Yentreve, and a 5-day wash-out period is required after stopping Yentreve before starting an MAOI.
Potent Inhibitors of CYP1A2, such as fluvoxamine, ciprofloxacin, or enoxacin, as these drugs significantly increase duloxetine blood levels.

Increased Risk of Side Effects

Caution and monitoring are advised when Yentreve is used with other medications:

Other Serotonergic Drugs: Co-administration with other medicines that affect serotonin levels (e.g., SSRIs, SNRIs, triptans, tramadol, or the herbal product St. John's Wort) increases the risk of Serotonin Syndrome.
Anticoagulants and Antiplatelet Agents: Drugs that affect blood clotting, such as warfarin, NSAIDs, or aspirin, may increase the risk of bleeding events, including gastrointestinal bleeding.
CYP2D6 Inhibitors: Potent inhibitors of the CYP2D6 enzyme can increase duloxetine exposure. Additionally, Yentreve itself is a moderate inhibitor of CYP2D6 and can increase the concentration of medicines metabolized by this enzyme.
CNS Depressants: Caution is warranted with drugs that act on the central nervous system and cause sleepiness, such as benzodiazepines or strong pain relievers, as the combined effect may be enhanced.

Mechanism of Action

Dual Reuptake Inhibition of Serotonin and Norepinephrine

Yentreve (duloxetine) operates as a selective inhibitor of the serotonin transporter (SERT) and the norepinephrine transporter (NET). By binding to these proteins on the presynaptic nerve terminals, the drug prevents the reuptake of the neurotransmitters serotonin (5-HT) and norepinephrine (NE) from the synaptic cleft. This action increases the concentration of both monoamines, which enhances nerve signaling in the central and peripheral nervous systems.

Neurochemical Modulation of the Lower Urinary Tract

Increased levels of norepinephrine modulate the efferent sympathetic signals transmitted via the spinal cord to the lower urinary tract (LUT). This activity targets the neural pathways responsible for regulating LUT function, initiating a downstream mechanistic cascade that affects smooth and striated muscle tone.

Physiological Consequences: Tone and Capacity

The enhanced sympathetic signaling produces two direct physiological consequences in the LUT: it promotes relaxation of the detrusor (bladder) muscle and increases the resting tonic contraction of the urethral sphincter. This combined effect raises the urethral outlet resistance and increases the functional capacity of the bladder.

Dosage and Administration Information

How to Use Yentreve: Official Administration Guidelines

This section outlines the standardized usage instructions for Yentreve (duloxetine) for the management of Stress Urinary Incontinence (SUI) in adult women.

Administration Details

Feature	Official Instruction
Route of Administration	The only approved method is oral use via the gastro-resistant capsules.
Capsule Handling	Capsules must be swallowed whole and must not be crushed or chewed.
Intake Conditions	The medication can be taken with or without food.

Dosage and Schedule

Feature	Official Regimen
Standard Recommended Dose	40 mg twice daily (B.I.D.) for a total daily dose of 80 mg.
Starting Dose	Treatment may begin with 20 mg twice daily for two weeks before increasing to the standard recommended dose.
Missed Dose	If a dose is missed, do not take a double dose; continue the regimen by taking the next scheduled dose at the usual time.

Use Over Time and Special Populations

Treatment is to be re-assessed after 2–4 weeks to determine continued benefit and tolerability. The overall benefit should be re-evaluated at regular intervals.

Usage is not recommended in individuals under 18 years of age. Furthermore, Yentreve must not be used in patients diagnosed with severe renal impairment (creatinine clearance <30 ml/min) or any form of hepatic impairment. When discontinuing the medicine, the dose should be gradually reduced over a period of at least one to two weeks.

Recent Clinical Evidence

Clinical Evidence for Moderate to Severe Stress Urinary Incontinence

The research base for Yentreve primarily consists of randomized, placebo-controlled clinical trials (RCTs). These short-term studies form the foundation of the evidence and are the type of research used to explore how a medicine is evaluated against an identical inactive pill (a placebo). The medicine was studied for its use in adult women who have been diagnosed with moderate to severe Stress Urinary Incontinence (SUI). This research focused specifically on how to assess outcomes related to daily functioning or activity level in this population.

The core efficacy trials typically covered a period of 12 weeks. In these studies, research explored how symptoms evolved in the observed populations when compared to the control group. Findings describe patterns observed in the studies regarding the change in patient-reported symptoms.

Outcomes Measured in Key Studies

Clinical trials research examined several key outcomes to monitor symptom patterns related to the condition. A primary focus was studied for the Incontinence Episode Frequency (IEF), which was monitored in studies using patient diaries. Studies also evaluated patient-reported outcomes describing perceived discomfort and how the condition affects daily life using specialized instruments like the Incontinence-Specific Quality of Life (I-QOL) questionnaire.

To understand the durability of observation, some patients participated in uncontrolled, open-label extension studies after the initial 12-week controlled period. These studies research examined the outcomes over a more extended timeframe, often providing data for up to six months to one year or more. However, because these extension studies lacked a placebo group for comparison, long-term effects are not fully established based on the same level of evidence as the initial controlled trials.

Research Gaps and Areas of Uncertainty

Follow-up durations were limited in the gold-standard, placebo-controlled research, meaning long-term effects are not fully established with high certainty. Additionally, comparative evidence is lacking for how Yentreve is evaluated directly against other major SUI interventions, such as different forms of Pelvic Floor Muscle Training. The evidence quality varies across studies when analyzing certain patient subgroups, meaning subgroup findings are uncertain.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Yentreve (FAQ)

Q: Is Yentreve the same as Cymbalta?

A: Yentreve and Cymbalta both contain the same active ingredient, duloxetine. However, they are prescribed for different, distinct approved conditions. Yentreve is officially indicated and approved only for treating Stress Urinary Incontinence (SUI) in adult women, whereas other brand names containing duloxetine (like Cymbalta) are approved for conditions such as depression and nerve pain. The official product information specifies Yentreve’s use only for SUI.

Q: How quickly does Yentreve start to work for bladder control?

A: Official prescribing guidance notes that the benefit and tolerability of the treatment is typically re-assessed after approximately two to four weeks of use. This initial check-in period is used by healthcare professionals to evaluate the patient's response and determine if treatment should continue.

Q: Can men ever be prescribed Yentreve for a similar issue?

A: According to the official product information, Yentreve is only indicated and approved for the treatment of moderate to severe Stress Urinary Incontinence (SUI) in adult women. Official documentation does not support its use in men, as its safety and effectiveness have not been established or approved for this indication in the male population.

Q: Is Yentreve safe to use for older adults?

A: Regulatory documents state that caution should be exercised when treating older adults. Older patients may have an increased risk of certain side effects, such as low sodium in the blood (hyponatremia), and the use of the medicine in this population may necessitate careful monitoring.

Q: Does alcohol interact negatively with Yentreve?

A: Official warnings note that the medication should not be prescribed to patients with substantial alcohol use or evidence of chronic liver disease. This is due to the potential for a serious side effect called hepatotoxicity, which is liver damage.

Q: Is it difficult to stop taking Yentreve once you've started?

A: Abrupt discontinuation should be avoided. When stopping the medicine after more than one week of therapy, the dose should generally be gradually reduced (tapered) over a period of at least one to two weeks. This tapering process is designed to lower the risk of experiencing discontinuation symptoms.

Q: Can you take Yentreve while breastfeeding?

A: Yentreve is not recommended for use in women who are breastfeeding. The official product information states that the active substance in the medication, duloxetine, is known to be excreted into human breast milk.

Q: Can I take Yentreve if I am taking supplements like St. John's Wort?

A: Official information advises that the herbal product St. John's Wort should be used with caution. Co-administration with Yentreve is associated with an increased risk of a serious condition called Serotonin Syndrome, which is related to excessive serotonin activity.

Q: Can Yentreve be taken with blood thinners?

A: Caution is advised if Yentreve is used alongside anticoagulants (blood thinners) or antiplatelet agents (like aspirin). This combination carries an increased risk of bleeding events, and the combination requires cautious management and monitoring.

Q: Does Yentreve affect libido or sexual function?

A: Yes, regulatory data indicates that the drug may cause symptoms of sexual dysfunction. Adverse effects such as decreased libido (sex drive) and other forms of abnormal sexual function have been reported in clinical trials.

Q: Why are people sometimes concerned about liver issues with Yentreve?

A: Concerns arise because official safety data reports instances of liver failure (hepatotoxicity), sometimes fatal, in patients treated with duloxetine. For this reason, Yentreve is officially contraindicated in patients with severe hepatic (liver) impairment.

Q: What is the typical dosage strength available for Yentreve?

A: Yentreve is supplied as hard gastro-resistant capsules. According to product information, the two available dosage strengths are 20 mg and 40 mg.

Q: Does Yentreve cause changes in mood or anxiety?

A: While Yentreve is not indicated for mental health conditions, the active ingredient is also an antidepressant. Regulatory labels note potential risks of anxiety, suicidal thoughts or behavior, and the activation of mania/hypomania, especially when starting treatment or changing doses.

Q: Can taking Yentreve cause weight gain or weight loss?

A: Yes, official data reports that both weight loss and weight gain have been observed in clinical trials. Patients experienced a mean weight loss in short-term studies, but a modest mean weight gain was seen in longer-term studies lasting up to one year.

Q: Can Yentreve interact with common over-the-counter pain relievers?

A: Caution is advised when using Yentreve with certain common over-the-counter pain relievers, specifically those that belong to the class of Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen or aspirin. Combining these with Yentreve may increase the risk of bleeding events.

Q: What if I take two Yentreve capsules by mistake?

A: If more than the prescribed amount is taken, contact with a healthcare professional is necessary immediately. Overdose symptoms reported can include sleepiness, vomiting, fast heart rate, and signs of Serotonin Syndrome.

Q: Can Yentreve affect sleep patterns?

A: Yes, sleep disturbances are a reported undesirable effect in the official safety profile. This can manifest as either insomnia (trouble falling or staying asleep) or somnolence (drowsiness).

Q: Is it possible to have an allergic reaction to Yentreve?

A: Yes. Yentreve is officially contraindicated in individuals who have a known hypersensitivity or allergy to duloxetine or any of its other ingredients. Severe skin reactions have been reported.

Q: Does Yentreve lose effectiveness over time?

A: Official guidelines require that treatment be re-assessed after 2–4 weeks and then at regular intervals to evaluate its continued benefit. This regular review process is in place to ensure the medication remains effective for the patient over time.

Q: What is the common reason for discontinuing Yentreve treatment?

A: In clinical trials, the most frequent reasons cited by patients for discontinuing treatment were experiencing adverse events. These commonly included side effects such as nausea, dizziness, and headache.

Q: Can Yentreve cause blurred vision?

A: Yes, according to the official safety profile, blurred vision is listed as a reported undesirable effect associated with the use of the medication.

How should Yentreve be stored and disposed of?

How to Store and Dispose of Yentreve (Duloxetine)

Yentreve (duloxetine hard gastro-resistant capsules) must be stored at controlled room temperature, specifically between 68 F and 77 F (20 C and 25 C). The medication must be protected from excess heat and moisture.

Handling and Safety

The capsules must be kept in the original container with the lid tightly closed. It is a mandatory labeled requirement that the capsules must be swallowed whole and not crushed, chewed, or opened to preserve the special coating. For safety, Yentreve must be stored out of the reach and sight of children.

Disposal Instructions

Disposal of unused or expired medication should utilize a drug take-back program when available. If a take-back program is not accessible, the product may be mixed with an undesirable substance (such as dirt or coffee grounds) and sealed in a bag for disposal in household trash. The medicine should not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.